May 2023 Editor's Choice: Prioritizing and achieving diversity in clinical trial enrollment

Beyond Anesthesia: Self-Hypnosis in ERAS Programs

Carcinosarcoma Wars: A New Hope for TROP-2 Therapeutic Targeting

To divert or not to divert: that is the question

Understanding the Implications of the Platinum-Free Interval in Endometrial Cancer

Prophylactic chemotherapy to prevent post-molar gestational trophoblastic disease - a long journey and a remarkable study

Clinical trials: Panacea or pitfall

FOLR1 status: Landscape beyond high grade serous ovarian cancer

Benefits of hormonal therapy for low grade serous ovarian cancer

Implementation and impact of a financial navigation program in gynecologic oncology

LVSI in Stage 1 Endometrial Cancer

Primary Surgery versus Radiotherapy for Inguinal Lymph Nodes in Vulvar Cancer

Shifting trends and sicker patients - the future of gynecologic cancer

2023 FIGO staging for endometrial cancer: a reappraisal on the path to continuous improvement

Editor's Choice: SENTIREC-endo study: Is the juice worth the squeeze?

Editor's Choice: Caring for the Caregiver

Editor’s Choice: Lunchbox Trial

Editor’s Choice: Engagement with ERAS patients leads to improved outcomes

October 2023 Editor’s Choice: OS updates for Imagyn50

September 2023 Editor’s Choice: Is now the time to begin thromboprophylaxis for all patients with advanced ovarian cancer, including those undergoing neoadjuvant chemotherapy?